Enliven Therapeutics Inc

ELVN

17.630USD

-0.670-3.66%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

Enliven Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

211 / 501

Overall Ranking

374 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.667

Target Price

+130.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Enliven Therapeutics Inc Highlights

StrengthsRisks

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Fairly Valued

The company’s latest PE is -10.71, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 61.37M shares, increasing 11.47% quarter-over-quarter.

Held by Stanley Druckenmiller

Star Investor Stanley Druckenmiller holds 463.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.48.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.76, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -10.71, which is -27.50% below the recent high of -7.76 and -20.62% above the recent low of -12.91.

Score

Industry at a Glance

Previous score

6.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 211/501

No Data

The company’s current earnings forecast score is 8.60, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Enliven Therapeutics Inc is 38.00, with a high of 52.00 and a low of 33.00.

Score

Industry at a Glance

Previous score

8.60

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.87, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 22.88 and the support level at 19.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

0.5

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 103.60%, representing a quarter-over-quarter increase of 6.75%. The largest institutional shareholder is The Vanguard, holding a total of 2.40M shares, representing 4.06% of shares outstanding, with 0.54% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

7.96M

--

Fidelity Management & Research Company LLC

7.03M

+27.33%

Commodore Capital LP

4.69M

+0.38%

VR Adviser, LLC

4.03M

--

Fairmount Funds Management LLC

3.71M

+15.88%

Polar Capital LLP

3.05M

+28.96%

BlackRock Institutional Trust Company, N.A.

2.65M

-2.00%

The Vanguard Group, Inc.

Star Investors

2.40M

+22.10%

Dalton Barbara J

2.54M

--

Janus Henderson Investors

1.72M

+9.29%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Enliven Therapeutics Inc

ELVN

5.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment